PLASMIN INHIBITOR INTERACTIONS

The Effectiveness of α2-Plasmin Inhibitor in the Presence of α2-Macroglobulin*

By PETER C. HARPEL

(From the Department of Medicine, Division of Hematology, The New York Hospital-Cornell Medical Center, New York 10021)

Plasmin is inhibited in vitro by several plasma protease inhibitors including α2-macroglobulin (1-3), α1-antitrypsin (1, 4, 5), C1 inactivator (6, 7), and antithrombin-heparin cofactor (8). When these inhibitors are compared in purified systems, α2-macroglobulin appears to be the dominant inhibitor.1-2 It is also an important inhibitor in vivo because when plasminogen activators are infused, plasmin-α2-macroglobulin complexes have been identified (9). Nevertheless, neither the role of plasma protease inhibitors in modulating intravascular proteolytic events is established, nor is it clear whether the entire spectrum of possible inhibitors has been fully defined.

For example, a newly recognized plasmin inhibitor, termed α2-plasmin inhibitor, has been shown to inhibit plasmin rapidly (10), thus adding a new aspect to considerations of the regulation of plasmin activity. In this communication, we present experiments which detail the interactions between α2-plasmin inhibitor and α2-macroglobulin in competing for plasmin.

Materials and Methods

Chemicals. All chemicals were reagent grade.

Plasma. Plasma for the purification of α2-macroglobulin, α2-plasmin inhibitor, and plasminogen was obtained from fresh whole blood collected in acid-citrate-dextrose anticoagulant.

Antisera. Rabbit antisera produced against the following human proteins were obtained from Behring Diagnostics, American Hoechst Corp., Somerville, N. J.: α1-antitrypsin, C1 inactivator, antithrombin-heparin cofactor, inter-a-trypsin inhibitor, and chymotrypsin inhibitor.

Plasminogen. Plasminogen from human plasma was purified by insoluble-lysine affinity chromatography as described by Deutsch and Mertz (11), followed by gel filtration chromatography (Bio-Gel A-0.5 m, Bio-Rad Laboratories, Richmond, Calif.). The final preparation possessed a specific activity of 20 CTA (Committee on Thrombolytic Agents) U/mg as assayed by a standard caseinolytic assay (12). Plasminogen was labeled with 125I by the technique of McConahey and Dixon (13). Chloramine-T, 0.3 ml of a 100-μg/ml solution, was added to plasminogen, 1.3 mg in 0.5 ml 0.15 M phosphate buffer, pH 7.4, containing 1 mCi of carrier-free 125I-sodium iodide. After a 5-min incubation at 0°C, 0.3 ml sodium metabisulfite (100 μg/ml) was added. The unbound sodium iodide was removed by gel filtration chromatography. Labeling occurred at 0.4 μCi/μg plasminogen.

Native or 125I-labeled plasminogen was activated at 25°C by incubation in a 5% glycerol solution containing 0.04 M Tris-0.016 M lysine-0.08 M NaCl at pH 9.0 (14) with 500 Abbot U of

* Supported by U. S. Public Health Service grant HL-18828 (Specialized Center for Research in Thrombosis).

1 Harpel, P. Manuscript submitted for publication.

2 Rosenberg, R. D., and P. C. Harpel. Manuscript submitted for publication.

THE JOURNAL OF EXPERIMENTAL MEDICINE • VOLUME 146, 1977 1033
FIG. 1. Interaction of plasmin with α2-plasmin inhibitor. Plasmin (P, 2.5 μg), gel a, and α2-plasmin inhibitor (α2-PI; 2.0 μg), gel b, were incubated together, gel c, for 2 min at 37°C. After incubation, these mixtures were analyzed in the absence of reduction, by electrophoresis on 5% SDS-acrylamide gels. The anode is toward the bottom of the figure. The location of the inhibitor-plasmin complex is indicated (α2PI-P Cx).

urokinase/mg zymogen. Conversion to plasmin was documented by sodium dodecyl sulfate (SDS)gel electrophoretic analysis of reduced samples of the plasminogen-urokinase incubation mixture which demonstrated complete conversion of the plasminogen band to the heavy and light chain of plasmin. Active site titration using p-nitrophenyl p'-guanidinobenzoate hydrochloride (p-NPGB) was performed as described by Chase and Shaw (15).

Human α2-Macroglobulin. Human α2-macroglobulin was prepared as previously described (16). The final product migrated as a single protein band after reduction as analyzed by SDS-acrylamide gel electrophoresis. Concentrations of α2-macroglobulin were established by radial immunodiffusion (Immuno Plate, Hyland Div. Travenol Laboratories, Inc., Costa Mesa, Calif.).

Human α2-Plasmin Inhibitor. Human α2-plasmin inhibitor was isolated from outdated blood bank plasma as described by Moroi and Aoki (10). Upon cellulose acetate electrophoresis, the final preparation demonstrated one band with α2-mobility. Upon SDS-gel electrophoresis, the material displayed a major band with an apparent Mw = 67,000, consistent with that obtained by Moroi. A minor contaminant, Mw = 64,000, probably similar to that reported by Moroi, was also apparent (Fig. 1, gel b). Using specific antibodies and double-diffusion analysis, no detectable α2-macroglobulin, CI inactivator, α2-antitrypsin, antithrombin-heparin cofactor, inter-α-trypsin inhibitor, or chymotrypsin inhibitor were identified in the α2-plasmin inhibitor preparation.

After incubation of α2-plasmin inhibitor with plasmin, SDS-gel electrophoretic analysis of the unreduced mixture demonstrated a loss of the protein bands in the α2-plasmin inhibitor and plasmin positions, and a new higher molecular weight band was identified (Fig. 1, gel c). The apparent Mw of this band was 142,000, consistent with the formation of a complex between plasmin (Mw = 75,000) and α2-plasmin inhibitor. The lower molecular weight band in Fig. 1, gels a and c, was a component of the urokinase preparation added to activate plasminogen.

The concentration of functionally active plasmin inhibitor in the final α2-plasmin inhibitor preparation was obtained by titration of a known concentration of plasmin with the inhibitor similar to the method described by Müllertz and Clemmensen (17). The inhibition of plasmin was found to be linearly related to the volume of inhibitor added to the incubation mixture containing plasmin and the substrate H-v-valyl-leucyl-lysine-p-nitroanilide. The concentration of active inhibitor was 101 μg/ml.

SDS-Polyacrylamide Gel Electrophoresis (5% gels). This was performed according to the method of Weber and Osborn (18). Samples for analysis were added to an equal volume of a solution containing 10 M urea and 2% SDS, and boiled for 5 min.

Abbreviations used in this paper: Mw, molecular weight; p-NPGB, p-nitrophenyl p'-guanidinobenzoate hydrochloride; SDS, sodium dodecyl sulfate.
PETER C. HARPEL 1035

Studies of the Binding of 125I-Plasmin to α2-Macroglobulin and α2-Plasmin Inhibitor. 125I-
Plasmin was prepared by the activation of 125I-plasminogen with urokinase as described above,
and the activity was established by active site titration with p-NPGB. The experimental condi-
tions in these binding studies used physiologic concentrations of α2-macroglobulin (3.5 μM (19))
since it has been found that this inhibitor is less effective in binding plasmin in more dilute
systems (unpublished observations). Since the α2-plasmin inhibitor reacts rapidly with plasmin
even at 0°C (10), all incubation mixtures containing the inhibitors were equilibrated at 37°C before
the addition of plasmin. Plasmin was added to α2-macroglobulin or to mixtures of α2-macroglo-
bulin and increasing concentrations of α2-plasmin inhibitor. The concentrations of α2-plasmin
inhibitor used in these studies (0.06-0.75 μM) were less than those found for normal plasma (1.1
μM (10)). The reaction was terminated by the addition of the SDS-urea solution and boiling. After
SDS-gel electrophoresis, the gels were sliced into 2-mm segments and counted in a Searle 1185
gamma counter (Searle Analytic Inc., Des Plaines, III.).

Amidolytic Assay. Standard plasmin curves were established using the substrate H-D-valyl-
leucyl-lysine-p-nitroanilide (AB Bofors Nobel Division, Molndal, Sweden) using minor modifi-
cations of the methods detailed by the manufacturers. A constant concentration of plasmin was
added to a constant concentration of α2-macroglobulin or to a mixture of α2-macroglobulin and
increasing concentrations of α2-plasmin inhibitor in the concentrations indicated in Table II. The
final incubation volume was 1.2 ml and contained 330 μg substrate. After a 15-min incubation at
37°C, 30% acetic acid (0.3 ml), was added to stop the reaction, and the absorbance was recorded at
410 nm. Residual plasmin activity was established from the linear plasmin standard curves. α2-
Macroglobulin was found not to inhibit the amidolytic activity of plasmin since the residual
activity of a mixture of α2-macroglobulin and plasmin was similar to the activity expressed by
plasmin alone.

Protein. Protein was measured by the Lowry procedure (20) with bovine serum albumin
(Pentex Biochemical, Kankakee, Ill.) as the reference standard.

Results

The Interaction of 125I-Plasmin with α2-Macroglobulin and α2-Plasmin Inhibi-
tor as Analyzed by SDS-Acrylamide Gel Electrophoresis. To define the relative
importance of purified α2-macroglobulin and α2-plasmin inhibitor as plas-
min inhibitors, the amount of 125I-plasmin bound to each in incubation mixtures
of the two was determined. This proved feasible as preliminary studies estab-
lished that complexes between radiolabeled plasmin and either inhibitor did not
dissociate after electrophoresis in SDS gels. Further, the electrophoretic mobi-
ity of the plasmin, α2-macroglobulin complex near the top of the gel1 was
sufficiently different from that of the plasmin, α2-plasmin inhibitor complex
(Fig. 1) to make it possible to separate these complexes in mixtures of inhibitors
and plasmin. Thus, analysis of incubation mixtures of 125I-plasmin, α2-macro-
globulin, and varying concentrations of α2-plasmin inhibitor by SDS-acrylamide
gel electrophoresis demonstrated the quantitative contribution of each in bind-
ing plasmin (Table I).

In the present studies, concentrations of plasmin were selected which were
well below the previously established 1 to 1 M binding capacity of α2-macroglo-
bulin.1 Under these conditions, comparison of the binding of 125I-plasmin to
mixtures of the inhibitors at 10 and 120 s of incubation demonstrated that the
reactions were complete by 10 s since no shift of radioactivity between inhibitor-
enzyme complexes was detected. As indicated in Table I, when a constant
amount of plasmin (0.28 μM) was added to α2-macroglobulin (3.5 μM) and
increasing concentrations of α2-plasmin inhibitor (0.06-0.75 μM), the α2-plas-
min inhibitor always bound nearly as much plasmin as it did in the absence of
### Table I

The Binding of \textsuperscript{125}I-Plasmin by \(\alpha_2\)-Plasmin Inhibitor in the Presence or Absence of \(\alpha_2\)-Macroglobulin: Effect of Varying the Concentration of \(\alpha_2\)-Plasmin Inhibitor

| Concentration \(\alpha_2\)-PI | \(\alpha_2\)M + \(\alpha_2\)-PI* | \(\alpha_2\)-PI† | \(\alpha_2\)-PI bound to \(\alpha_2\)M | \(\alpha_2\)-Plasmin bound to \(\alpha_2\)-PI |
|-----------------------------|-----------------------------|-----------------|----------------|----------------|
| \(\mu\text{M}\)            | \(\%\)                      | \(\%\)          | \(\%\)         | \(\%\)         |
| 0                           | 46.6                        | –               | –              | –              |
| 0.06                        | 41.3                        | 5.9             | 0              | 0              |
| 0.13                        | 36.9                        | 11.7            | 11.0           | 32.9           |
| 0.38                        | 12.7                        | 29.9            | 32.9           | 32.9           |
| 0.75                        | 5.4                         | 38.0            | 40.0           | 40.0           |

* 5 \(\mu\text{l}\) \textsuperscript{125}I-plasmin (0.28 \(\mu\text{M}\) final concentration) was added to a mixture of 10 \(\mu\text{l}\) \(\alpha_2\)-macroglobulin (\(\alpha_2\)M; 3.5 \(\mu\text{M}\) final concentration) and 5 \(\mu\text{l}\) buffer (0 \(\mu\text{M}\) \(\alpha_2\)-PI) at 37°C, or to a mixture containing \(\alpha_2\)M and 5 \(\mu\text{l}\) of the concentrations of \(\alpha_2\)-plasmin inhibitor (\(\alpha_2\)-PI) indicated in the table. For these concentrations of \(\alpha_2\)-PI, the molar ratios relative to the concentration of \(\alpha_2\)M (3.5 \(\mu\text{M}\)) are as follows: 0.06 \(\mu\text{M}\) = 0.02; 0.13 \(\mu\text{M}\) = 0.4; 0.38 \(\mu\text{M}\) = 0.11; 0.75 \(\mu\text{M}\) = 0.21.

After a 10-s incubation, a solution of SDS and urea was added to terminate the reaction. The mixtures were then analyzed by SDS-acrylamide gel electrophoresis, and 2-mm gel segments were counted in a gamma counter.

† 5 \(\mu\text{l}\) \textsuperscript{125}I-plasmin (0.28 \(\mu\text{M}\)) was incubated with buffer (0 \(\mu\text{M}\) \(\alpha_2\)-PI) or with varying concentrations of \(\alpha_2\)-PI as indicated in the table and under the conditions described above. No \(\alpha_2\)-macroglobulin was included in these mixtures.

§ Percent plasmin bound was calculated as the counts per minute associated with the \textsuperscript{125}I-plasmin-\(\alpha_2\)-macroglobulin complex or with the \textsuperscript{125}I-plasmin-\(\alpha_2\)-plasmin inhibitor complex divided by the sum of the cpm of these complexes plus the radioactivity of the unbound plasmin. All values are the mean of duplicate determinations.

This effect was apparent in \(\alpha_2\)-plasmin inhibitor to \(\alpha_2\)-macroglobulin molar ratios as small as 0.02.

The amount of the radiolabeled plasmin which was identified in complexes with the inhibitors (46%) was in agreement with the results of active site titration of the plasmin preparation used, which demonstrated a 50% activity. For reasons which are poorly understood, in the mixture of enzyme and inhibitor with the lowest concentration of \(\alpha_2\)-plasmin inhibitor (0.06 \(\mu\text{M}\)), no inhibitor-plasmin complex was identified after SDS-gel electrophoresis (three experiments), although binding to this concentration of inhibitor was detectable in the presence of \(\alpha_2\)-macroglobulin.

In other experiments not shown in Table I, preincubation of \(\alpha_2\)-macroglobulin (3.5 \(\mu\text{M}\)) with \textsuperscript{125}I-plasmin for 2 min at 37°C, followed by the addition of \(\alpha_2\)-plasmin inhibitor (0.75 \(\mu\text{M}\)) for a similar incubation period, demonstrated that all the active plasmin remained bound to \(\alpha_2\)-macroglobulin and none became associated with the \(\alpha_2\)-plasmin inhibitor. In an experiment reversing the addition sequence in which \textsuperscript{125}I-plasmin was added to \(\alpha_2\)-plasmin inhibitor first followed by addition of \(\alpha_2\)-macroglobulin, plasmin was identified in the \(\alpha_2\)-plasmin inhibitor, plasmin complex, and none became associated with \(\alpha_2\)-
macroglobulin. Thus, we conclude that after initial binding, there is no transfer of enzyme from one inhibitor to the other.

**The Binding of Plasmin to \( \alpha_2 \)-Macroglobulin in the Presence of \( \alpha_2 \)-Plasmin Inhibitor as Determined by an Amidolytic Assay.** To test for the binding of unlabeled, native plasmin to \( \alpha_2 \)-macroglobulin in the presence of varying concentrations of \( \alpha_2 \)-plasmin inhibitor, a second technique was utilized. This method of analysis was made possible by the observation that the hydrolytic activity of plasmin against low molecular weight substrates was preserved after complex formation with \( \alpha_2 \)-macroglobulin (3, 21). We first established that the hydrolysis of the chromogenic synthetic peptide H-D-valyl-L-leucyl-L-lysine-p-nitroanilide by plasmin was inhibited completely by \( \alpha_2 \)-plasmin inhibitor, but was not inhibited when plasmin was bound to \( \alpha_2 \)-macroglobulin. Furthermore, we established that \( \alpha_2 \)-plasmin inhibitor caused negligible inhibition of the amidolytic activity of the \( \alpha_2 \)-macroglobulin–plasmin complex. Therefore, when plasmin is added to mixtures of both inhibitors, the amount of enzyme bound to \( \alpha_2 \)-macroglobulin can be quantitated by the preservation of amidolytic activity.

Assays using this substrate confirmed the effectiveness of \( \alpha_2 \)-plasmin inhibitor in competing with \( \alpha_2 \)-macroglobulin for plasmin (Table II). Increasing concentrations of \( \alpha_2 \)-plasmin inhibitor in a mixture of a constant concentration of plasmin and \( \alpha_2 \)-macroglobulin caused a reduction in the amidolytic activity of the incubation mixture which was proportional to the final concentration of \( \alpha_2 \)-plasmin inhibitor added. Comparison of the plasmin activity of the incubation mixtures containing \( \alpha_2 \)-plasmin inhibitor and plasmin with those mixtures which also included \( \alpha_2 \)-macroglobulin demonstrated no significant differences. Thus, the \( \alpha_2 \)-plasmin inhibitor competed with \( \alpha_2 \)-macroglobulin as effectively for native plasmin as it did for the radiolabeled enzyme.

**Discussion**

Previous studies from our laboratory have examined the interactions between plasmin and mixtures of purified plasma protease inhibitors in the concentrations found in plasma. In mixtures containing \( \alpha_2 \)-macroglobulin, \( \alpha_1 \)-antitrypsin, and C1 inactivator, the \( \alpha_2 \)-macroglobulin was found to bind most of the plasmin which was added. In a similar analysis, \( \alpha_2 \)-macroglobulin competed effectively for plasmin in the presence of antithrombin-heparin cofactor. The addition of heparin, however, enabled the antithrombin-heparin cofactor to bind slightly more plasmin than did the \( \alpha_2 \)-macroglobulin. Thus, in the competition among plasma inhibitors for plasmin in the absence of heparin, \( \alpha_2 \)-macroglobulin binds plasmin more rapidly than does \( \alpha_1 \)-antitrypsin, C1 inactivator, and antithrombin-heparin cofactor.

Moroi and Aoki (10) have recently isolated a plasma inhibitor of plasmin, termed the \( \alpha_2 \)-plasmin inhibitor, which rapidly formed a complex with plasmin and which completely inhibited the proteolytic and esterolytic activity of the enzyme. This inhibitor appears to be identical to the partially purified, rapidly acting plasmin inhibitor described by Müllertz and Clemmensen (17). Both Müllertz (22) and Collen (23) have documented that in vitro activation of small amounts of plasminogen in plasma results in the appearance of the \( \alpha_2 \)-plasmin inhibitor–plasmin complex, which precedes the formation of the plasmin–\( \alpha_2 \)-
**PLASMIN INHIBITOR INTERACTIONS**

**Table II**

*Effect of Varying the Concentration of α₂-Plasmin Inhibitor on the Binding of Plasmin to α₂-Macroglobulin as Assayed Using a Tripeptide Substrate for Plasmin*

| Concentration α₂-PI (μM) | α₂M + α₂-PI* μM | α₂-PI† μM |
|--------------------------|------------------|-----------|
| 0                        | 0.39             | 0.39      |
| 0.06                     | 0.37             | 0.35      |
| 0.13                     | 0.29             | 0.31      |
| 0.25                     | 0.14             | 0.12      |
| 0.5                      | 0.03             | 0.0      |

* 5 μl plasmin (0.4 μM final concentration of plasmin as determined by active site titration with p-NPGB) was added to a mixture of 5 μl α₂-macroglobulin (4.6 μM final concentration) and 5 μl buffer (0 μM α₂-PI) at 37°C, or to a mixture containing α₂M and 5 μl of the concentrations of α₂-plasmin inhibitor indicated in the table. For these concentrations of α₂-PI, the molar ratios relative to the concentration of α₂M (4.6 μM) are as follows: 0.06 μM = 0.01; 0.13 μM = 0.03; 0.25 μM = 0.05; 0.5 μM = 0.11.

† 5 μl plasmin (0.4 μM) was incubated with buffer (0 μM α₂-PI) or with varying concentrations of α₂-PI as indicated in the table and under the conditions described above. No α₂-macroglobulin was included in these mixtures.

In the present study, we have examined directly the ability of α₂-plasmin inhibitor to bind plasmin in the presence of α₂-macroglobulin. The results of two different methods designed to assess complex formation between plasmin and these inhibitors were entirely comparable and indicated that ¹²⁵I-plasmin bound as readily to these inhibitors as did the native enzyme. Comparison of the distribution of radiolabeled plasmin between the two inhibitors at 10 and 120 s of incubation showed an identical binding pattern, indicating that the reactions were rapid, being completed by 10 s. Preincubation of plasmin with one inhibitor followed by the addition of the other established that transfer of the enzyme between the inhibitors did not occur.

The reported plasma concentration of α₂-plasmin inhibitor (1.1 μM [10]), and of α₂-macroglobulin (3.5 μM [16]), represents a molar ratio of 0.3. In our binding studies, α₂-plasmin inhibitor to α₂-macroglobulin molar ratios from 0.01 to 0.21

macroglobulin complex. These observations suggest that the α₂-macroglobulin may function as a plasmin inhibitor after the saturation of the α₂-plasmin inhibitor.
have been examined. Over this range of α₂-plasmin inhibitor concentrations, approximately as much plasmin was bound to the α₂-plasmin inhibitor in mixtures which contained α₂-macroglobulin as in those which did not. This indicates that when both inhibitors simultaneously compete for plasmin, the α₂-plasmin inhibitor binds the enzyme much more rapidly than does the α₂-macroglobulin. These data strengthen the concept that the α₂-plasmin inhibitor may represent the primary plasmin inhibitor in the circulating blood.

Summary

α₂-Plasmin inhibitor and α₂-macroglobulin were allowed to compete for the protease plasmin. The binding of the enzyme to these inhibitors was assessed by two different but comparable methods. The interactions were completed in 10 s of incubation, and transfer of plasmin from one inhibitor to the other did not occur. Almost as much plasmin was bound to α₂-plasmin inhibitor in mixtures containing a large molar excess of α₂-macroglobulin relative to plasmin or α₂-plasmin inhibitor, as was bound in mixtures not containing α₂-macroglobulin. These studies demonstrate directly the effectiveness of α₂-plasmin inhibitor in binding and inhibiting plasmin in the presence of α₂-macroglobulin, and suggest that the α₂-plasmin inhibitor may be the major circulating plasmin inhibitor.

The technical assistance of Ms. Linda Nyari, Mr. T. S. Chang, and Mr. J. Olson is gratefully acknowledged. I wish to thank Dr. Ralph Nachman and Dr. Michael Mosesson for their review of this manuscript, and for their helpful suggestions.

Received for publication 20 May 1977.

References

1. Norman, P. S., and B. M. Hill. 1958. Studies of the plasmin system. III. Physical properties of two plasmin inhibitors in plasma. J. Exp. Med. 108:639.
2. Schultze, H. E., N. Heimburger, K. Heide, H. Haupt, K. Störiko, and H. G. Schwick. 1963. Preparation and characterization of α₁-trypsin inhibitor and α₂-plasmin inhibitor of human serum. Proc. Congr. Eur. Soc. Haematol. 9:1315. (Abstr.)
3. Ganrot, P. O. 1967. Inhibition of plasmin activity by α₂-macroglobulin. Clin. Chim. Acta. 16:328.
4. Rimon, A., Y. Shamash, and B. Shapiro. 1966. The plasmin inhibitor of human plasma. J. Biol. Chem. 241:5102.
5. Gans, H., and B. H. Tan. 1967. α₁-Antitrypsin, an inhibitor for thrombin and plasmin. Clin. Chim. Acta. 17:111.
6. Ratnoff, O. D., J. Pensky, D. Ogston, and G. B. Naff. 1969. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C1r subcomponent of the first component of complement by serum C1 esterase inhibitor. J. Exp. Med. 129:315.
7. Harpel, P. C., and N. R. Cooper. 1975. Studies on human plasma Cl⁻ inactivator enzyme interactions. I. Mechanisms of interaction with Cl₁s, plasmin and trypsin. J. Clin. Invest. 55:593.
8. Highsmith, R. F., and R. D. Rosenberg. 1974. The inhibition of human plasmin by human antithrombin-heparin cofactor. J. Biol. Chem. 249:4335.
9. Nilén, J. E., and P. O. Ganrot. 1967. Plasmin, plasmin inhibitors and degradation products of fibrinogen in human serum during and after intravenous infusion of streptokinase. Scand. J. Clin. Lab. Invest. 20:113.
1040 PLASMIN INHIBITOR INTERACTIONS

16. Moroi, M., and N. Aoki. 1976. Isolation and characterization of \( \alpha_2 \)-plasmin inhibitor from human plasma. *J. Biol. Chem.* 251:5956.

17. Deutsch, D. G., and E. T. Mertz. 1970. Plasminogen: purification from human plasma by affinity chromatography. *Science (Wash. D. C.)*. 170:1095.

18. Alkjaersig, N., A. P. Fletcher, and S. Sherry. 1959. e-Aminocaproic acid: an inhibitor of plasminogen activation. *J. Biol. Chem.* 234:832.

19. McConahey, P. J., and F. J. Dixon. 1966. A method of trace iodination of proteins for immunologic studies. *Int. Arch. Allergy Appl. Immunol.* 29:185.

20. Summaria, L., L. Arzadon, P. Bernabe, and K. C. Robbins. 1973. Isolation, characterization, and comparison of the S-carboxymethyl heavy (A) and light (B) chain derivatives of cat, dog, rabbit, and bovine plasmins. *J. Biol. Chem.* 248:8522.

21. Chase, T., and E. Shaw. 1969. Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes. *Biochemistry.* 8:2212.

22. Harpel, P. C. 1976. Human \( \alpha_2 \)-macroglobulin. *Methods Enzymol.* 45:639.

23. Müllertz, S., and I. Clemmensen. 1976. The primary inhibitor of plasmin in human plasma. *Biochem. J.* 159:545.

24. Weber, K., and M. Osborn. 1969. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. *J. Biol. Chem.* 244:4406.

25. Harpel, P. C., and R. D. Rosenberg. 1976. \( \alpha_2 \)-Macroglobulin and antithrombin-heparin cofactor: modulators of hemostatic and inflammatory reactions. *Prog. Hemo-
stasis Thromb.* 3:145.

26. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 193:265.

27. Harpel, P. C., and M. W. Mosesson. 1973. Degradation of human fibrinogen by plasma \( \alpha_2 \)-macroglobulin-enzyme complexes. *J. Clin. Invest.* 52:2175.

28. Müllertz, S. 1974. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin. *Biochem. J.* 143:273.

29. Collen, D. 1976. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. *Eur. J. Biochem.* 69:209.